about
Humidification of indoor air for preventing or reducing dryness symptoms or upper respiratory infections in educational settings and at the workplaceHealth-related quality of life and its association with medication adherence in active pulmonary tuberculosis- a systematic review of global literature with focus on South AfricaHealth-related quality of life in South African patients with pulmonary tuberculosis.Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011Statin use and risk of cholecystectomy - A case-control analysis using Swiss claims data.Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons.Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.Estimating healthcare costs of acute gastroenteritis and human campylobacteriosis in SwitzerlandDiagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trialSubgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications.Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland.The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsMultivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factorsPAIN OUT: an international acute pain registry supporting clinicians in decision making and in quality improvement activities.Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaPlanning and reporting of quality-of-life outcomes in cancer trials.Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UKCost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Learning from failure--rationale and design for a study about discontinuation of randomized trials (DISCO study).Economic efficiency of gate-keeping compared with fee for service plans: a Swiss exampleHow to Evaluate Health-Related Quality of Life and Its Association with Medication Adherence in Pulmonary Tuberculosis - Designing a Prospective Observational Study in South Africa.Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials.Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practicePegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.Improvement of cardiovascular risk prediction: time to review current knowledge, debates, and fundamentals on how to assess test characteristics.Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation.Prevalence, characteristics, and publication of discontinued randomized trials.Premature Discontinuation of Randomized Trials in Critical and Emergency Care: A Retrospective Cohort Study.Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).
P50
Q26471791-59B6D4D4-DEAD-4D25-A0F4-9027B6B8781AQ26766241-19A9DACA-5E12-4FCA-8855-C6942AB2C913Q30061732-35659114-1194-44DA-9063-26EE2565615AQ30828781-5306FD99-9350-43CA-BB63-8D80225525DBQ31133438-05879D66-E592-4EED-ACA7-D6FC40F17255Q31154313-03A77573-69DF-4229-B3CE-1AE0EA1DFD7FQ33357024-6C0E3C9C-C12B-443B-AB91-C699952A2D4DQ33389472-7D4AAB28-9776-46E8-B6D2-D986282F57F3Q33543823-89995891-259B-4467-8AEA-856B386BCD93Q33662036-F37731C6-C5FC-4F21-87C2-699897850FC4Q33854806-FBE39509-9AE8-4624-8359-51B0DAEFD792Q33909616-BB000191-081D-4CE6-9648-0861D9B772D1Q33913975-729FD953-DFEF-4A77-98EA-CA52B70F88D2Q34104990-A94448F6-280D-4ACD-95AE-A8F16F170FB4Q34353022-CC90E8C5-ACD1-43CC-BF51-DB22EAD2A098Q34636362-8AF17E45-99D3-4627-BBB0-A7C7A4DD9B23Q34871753-F9271925-DE9C-438B-91EC-3698961750C3Q35008290-D04F3488-4423-4213-8230-91B9F09E87ADQ35123683-2BCA51FB-19C4-48E8-8C61-9BCCD38B3AEBQ35199788-780C20A9-AAF3-4F8F-8122-24E26EEBFD35Q35303471-7465A2AA-02BD-4B5D-B4C3-4338BE1AC7A8Q35606843-A66916BD-3405-40E9-A2F6-D84BA9365E4FQ35730160-3A080A5F-DC6F-45E9-9B7F-DC13454DAEE6Q36000225-4F038DB5-43FB-4389-9936-561544C1A909Q36050640-DBC022AD-8C1F-4E7B-A6B5-156D1D548AA9Q36322947-EBEE7FCA-D56F-433C-A825-91B2CE50E8E0Q36483995-88EC526A-6ADD-4CEE-AEDC-B8B051F2F4B7Q36768573-8F05DF68-19FF-46C9-8B06-987F5BAAB2BAQ36950648-AA0EACF4-3F16-498D-A743-DB06C2796119Q37046876-97E430A7-328F-4E2F-98FC-A41FFCDB63D0Q37358759-2D3875A9-C763-4A33-82BE-D54870875F60Q37554901-F9F7EED4-941A-4D96-8A6E-B5ED2228F791Q37596004-AD83167E-B0FD-4BB5-B745-780B75A523FFQ37642528-1990593B-0AB8-432F-BB5E-8AB160B922DFQ37893527-960DA6E2-0277-4955-9F93-5B31A75DF20FQ38063718-3D5CAAA8-0E62-4637-BA5C-F3D06A922536Q38392593-39A51E93-4224-466F-9084-5DB53EDCE587Q38607677-6EC47D9E-C1E7-4A96-BBDE-0E21621BD3A0Q38710744-6A7BBBFB-497C-4B7D-800D-352672F7E43BQ38726493-EC756478-FDF9-4C80-8A57-CD06DA8FA71D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-7217-1173
@en
name
Matthias Schwenkglenks
@ast
Matthias Schwenkglenks
@en
Matthias Schwenkglenks
@es
Matthias Schwenkglenks
@sl
type
label
Matthias Schwenkglenks
@ast
Matthias Schwenkglenks
@en
Matthias Schwenkglenks
@es
Matthias Schwenkglenks
@sl
prefLabel
Matthias Schwenkglenks
@ast
Matthias Schwenkglenks
@en
Matthias Schwenkglenks
@es
Matthias Schwenkglenks
@sl
P106
P21
P31
P496
0000-0001-7217-1173